CONMED Corporation announced that the 2020 Annual Meeting of Shareholders will be held on May 21, 2020 at 1:30 p.m. ET.
UTICA, N.Y.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced that the 2020 Annual Meeting of Shareholders will be held on May 21, 2020 at 1:30 p.m. ET. Shareholders as of the close of business on the record date, April 3, 2020, will be eligible to attend, vote at, and participate in the Annual Meeting.
Due to an Executive Order prohibiting public gatherings in New York State amid public health and safety concerns arising from the COVID-19 pandemic, the 2020 Annual Meeting of Shareholders will be held virtually.
The State of New York typically requires shareholder meetings to accommodate in-person attendance; however, a temporary exception to this rule has been granted. As of the date of this press release, this exception will remain in place through April 19, 2020. The Company currently anticipates that this exception will be extended; however, if legally required by the State to accommodate in-person attendance, the Company will allow a legally permitted number of shareholders to attend the Annual Meeting in person on a first-come, first-served basis. If and when that determination is made, instructions for how to be considered for in-person attendance will be communicated in the future on the Company’s web site and in the Company’s proxy filings.
Information about the virtual meeting webcast and instructions for how shareholders can participate in the Annual Meeting will be included in either the definitive proxy statement or a proxy supplement for the Annual Meeting to be filed with the Securities and Exchange Commission and available on the investor relations page of our web site at www.conmed.com/en/about us/investors/investor relations.
About CONMED Corporation
CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology. For more information, visit www.conmed.com.
SOLICITATION LEGEND
Additional Information and Where to Find It
This communication may be deemed to be solicitation material in respect of the proposals to be voted on in connection with the 2020 annual meeting of shareholders of CONMED Corporation (the “Company”), including the election of directors. The Company filed a preliminary proxy statement on Schedule 14A with the Securities and Exchange Commission (“SEC”) on March 16, 2020 in connection with the solicitation of proxies for its 2020 annual meeting of shareholders or any adjournment or postponement thereof (the “2020 Annual Meeting”). The Company intends to file other relevant materials with the SEC, including a proxy statement in definitive form, in connection with the 2020 Annual Meeting. This document is not a substitute for the proxy statement or any other document which the Company may file with the SEC. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain free copies of the proxy statement (when available) and other documents that the Company files with the SEC from the SEC’s website at www.sec.gov or the Company’s investor relations website at https://www.conmed.com/en/about-us/investors/investor-relations as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.
Participants in the Solicitation
The Company and certain of its directors and executive officers may be deemed participants in the solicitation of proxies from shareholders in connection with the matters to be considered at the Company’s 2020 Annual Meeting. Certain information regarding these directors and executive officers and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Company’s definitive proxy statement for the 2020 Annual Meeting and other relevant documents to be filed with the SEC. Information regarding the Company’s directors and executive officers is currently available in the Company’s definitive proxy statement for its 2019 annual meeting of shareholders filed with the SEC on April 12, 2019 and the Company’s preliminary proxy statement for the 2020 Annual Meeting filed with the SEC on March 16, 2020. All documents filed by the Company with the SEC will be available free of charge from the sources indicated above.
Forward-Looking Statements
This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results, developments and events to differ materially from those in the forward-looking statements may include, but are not limited to, the risk factors discussed in the Company’s Annual Report on Form 10-K for the full year ended December 31, 2019. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. Forward-looking statements speak only as of the date made, and the Company disclaims any obligation to update or revise any forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005732/en/
CONMED Corporation
Todd Garner
Chief Financial Officer
315-624-3317
ToddGarner@conmed.com
Source: CONMED Corporation
View this news release online at:
http://www.businesswire.com/news/home/20200331005732/en